Automate theme → scenario → plan
In the app, we make it easy to go from investment themes to Scenario Lab to a full thesis plan — without the busywork.
Eli Lilly's Growth Potential Amid Competitive Landscape
LLY|June 28, 2026
Merkapital proprietary research generated from the same Thesis Plan engine (news narrative → scenario overlay → risk framework → listed-options context). For information only — not a recommendation or personalized advice.
Executive Summary
- •Thesis: Eli Lilly is capitalizing on its GLP-1 success while expanding into new markets, but faces competition and market volatility.
- •Reference spot: $1,208.12 · Scenario-implied fair value: — · Upside anchor: $1,222.62 (~+1.2% vs spot)
- •Risk framework: Volatility-adjusted stop at $1,146.94 (~5.1% below spot); risk/reward 0.24 : 1 vs modeled upside anchor.
- •Derivatives: Listed options snapshot unavailable (No valid bull call spread for ~6m / ~12m expirations (illiquid chain or R:R filter)).
Overview metrics
Quantitative snapshot from the Merkapital dashboard (same fields as Stocks → Overview Metrics), frozen at Thesis Plan save time.
Merkapital proprietary research (public sample)
Key developments & media context
Catalyst / news flow (seed narrative)
The following item was flagged in Market Intelligence and used as the primary media input for this note. It frames the narrative that the Thesis Plan engine then maps into scenarios, risk/reward, and options structure — it is not a stand-alone fundamental view.
Headline-level classification and feed sentiment skew constructive (risk-on). We treat this item as the narrative seed for the bull / base / bear structure and scenario overlay that follow — not as a standalone forecast.
Primary headline
Eli Lilly dives into hair loss treatments with investment in AI startup Absci - STAT News
Feed tone label: Somewhat-Bullish.
LLY · LLY · LLY · LLY · LLY
New Investment.
https://www.statnews.com/2026/06/24/eli-lilly-absci-hair-loss-treatments/
Merkapital proprietary research (public sample)
Revenue scenario
The following reflects consolidated revenue and segment mix assumptions recorded at the time this report was generated, benchmarked to the mapped segment disclosure and SEC-sourced consolidated revenue where applicable. Competitive positioning and filing references are provided for context only. These amounts represent hypothetical scenario inputs prepared in the research workflow and are not forecasts, targets, or projections of actual results.
Scenario basis: Forward analyst revenue estimate for the period ending December 31, 2027. Segment mix is benchmarked to the competitive map segment disclosure (FY 2025 (period end 2025-12-31)).
| Segment | Map % | Thesis % |
|---|---|---|
| Diabetes Care | 45.0% | 45.0% |
| Oncology | 25.0% | 25.0% |
| Neuroscience | 15.0% | 15.0% |
| Other Pharmaceuticals | 10.0% | 10.0% |
| Animal Health | 5.0% | 5.0% |
leader
$65.18B
FY 2025 (period end 2025-12-31)
Diabetes Care · Oncology · Neuroscience · Other Pharmaceuticals · Animal Health
Merkapital proprietary research (public sample)
Scenario Lab
Earnings and multiple assumptions from the Thesis Plan wizard (step 3), prior to the execution plan below.
- Last close
- $1,208.12
- Consensus EPS (next FY, baseline)
- —
- Scenario EPS
- —
- Forward P/E (baseline)
- —
- Scenario forward P/E
- —
- Street-implied (baseline)
- $1,222.62
- Scenario implied fair value
- $1,222.62
- Analyst target
- $1,222.62
- Scenario vs spot
- +1.2%
Frozen at Thesis Plan save; does not update with live quotes.
Merkapital proprietary research (public sample)
Valuation & Scenario Overlay
| Metric | Value |
|---|---|
| Last / model spot | $1,208.12 |
| Consensus analyst target (where available) | $1,222.62 |
| Scenario Lab implied price | — |
| Thesis upside anchor (options / R:R) | $1,222.62 |
| ATR-style volatility proxy (14d scale) | $40.79 |
| Annualized vol (model) | 33.5% |
| Risk per share (spot − stop) | $61.18 |
| Reward per share (anchor − spot) | $14.50 |
Merkapital proprietary research (public sample)
Risk Management & Invalidation
Volatility-adjusted stop: consider closing or reducing if price ≤ $1146.94 (entry − 1.5× ATR proxy using model volatility). Scenario upside anchor: $1222.62. Educational workflow only — not advice.
Merkapital proprietary research (public sample)
Listed Options — Expression of View
Structures are algorithmically selected from available chains (bull call spread; ~6m and ~12m anchors). Quotes may be delayed; liquidity and execution assumptions not modeled here.
No valid bull call spread for ~6m / ~12m expirations (illiquid chain or R:R filter)
Merkapital proprietary research (public sample)
Investment Thesis Map
Eli Lilly's Growth Potential Amid Competitive Landscape
Rotations & relative value
As LLY continues to innovate and expand, investors may rotate out of ABBV, which could face headwinds from LLY's growth.
Constructive angles
Eli Lilly's strategic investments in new treatments and technologies position it for robust growth.
LLY
Recent headlines highlight Lilly's investment in AI for hair loss treatments and its strong performance driven by GLP-1 revenues.
Mechanism: Continued innovation and expansion into new therapeutic areas can drive future revenue growth.
Strong stock performance indicates positive market sentiment and investor confidence in LLY.
LLY
LLY stock surged by over 6% recently, reflecting bullish sentiment among investors.
Mechanism: Positive stock movements can attract more institutional investors, further driving up the stock price.
Eli Lilly's acquisitions and investments enhance its competitive positioning.
LLY
The company is actively pursuing acquisitions to bolster its product pipeline, as seen in its shopping spree in Boston.
Mechanism: Acquisitions can lead to synergies and expanded market share, enhancing long-term growth prospects.
Cautious / bearish angles
Increased competition in the pharmaceutical sector may pressure LLY's market share.
ABBV, JNJ
Competitors like AbbVie and Johnson & Johnson are also performing well, potentially eroding LLY's dominance.
Mechanism: Heightened competition can lead to pricing pressures and reduced margins.
Market volatility and economic uncertainty could negatively impact LLY's stock performance.
LLY
Broader market trends and economic factors may create headwinds for growth stocks like LLY.
Mechanism: Economic downturns can lead to reduced healthcare spending and impact pharmaceutical sales.
Second-order effects
- Increased focus on AI and technology in pharmaceuticals may lead to more investments in biotech startups.
- If LLY's new treatments succeed, it could trigger a wave of similar investments across the industry.
Risks & invalidation
- Failure to successfully integrate new acquisitions could hinder growth.
- Regulatory challenges or negative clinical trial results could impact LLY's product pipeline.
Suggested news monitors
Eli Lilly acquisitions · LLY stock performance · pharmaceutical competition · GLP-1 market trends
This document is generated by Merkapital's research tooling for informational and educational purposes only. It does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security or derivative. Scenario outputs depend on user inputs and model assumptions; actual results may differ materially.
Options involve substantial risk and are not suitable for all investors. Past performance does not guarantee future results.
Automate theme → scenario → plan
Build investment themes, stress-test them in Scenario Lab, and turn the winner into a thesis plan — faster than spreadsheets and copy-paste.
Create your 10x idea today